US cancer centers are grappling with an influx of patient requests for an experimental pancreatic cancer drug , daraxonrasib, as they navigate an early access program while awaiting what many hope will be swift Food and Drug Administration (FDA) approval. The FDA gave the green light to the expanded access program on 1 May, a mere three weeks after Revolution Medicines, the drug's developer, announced that its once-daily pill had doubled survival rates in a clinical trial for patients with advanced pancreatic cancer. This form of cancer is notoriously aggressive, with one of the lowest five-year survival rates. Revolution Medicines had sought permission from the FDA to provide the drug free-of-charge to patients with previously treated pancreatic cancer that had metastasized. "The public caught wind of the FDA announcement... which has triggered a deluge of patient requests," said Dr. Daniel King, a medical oncologist at the Zuckerberg Cancer Center of Northwell Health.…